PMID- 37861945
OWN - NLM
STAT- Publisher
LR  - 20231020
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2023 Oct 20
TI  - Third-Generation Thyrotropin Receptor Antibody (TRAb) assay for predicting 
      neonatal thyroid dysfunction in pregnant women with Graves' disease.
LID - 10.1007/s12020-023-03569-3 [doi]
AB  - PURPOSE: The aim is to validate the third generation Thyrotropin receptor 
      antibody (TRAb) assay for predicting neonatal thyroid dysfunction and adverse 
      pregnancy outcomes in pregnant women with Graves' disease. METHODS: This 
      prospective cohort study was conducted in TRAb positive pregnant women with 
      Graves' disease and their off springs. The primary outcome was to assess 
      different forms of neonatal thyroid dysfunction in relation to maternal and 
      neonatal TRAb levels. The secondary outcome was to predict adverse pregnancy 
      outcomes by using maternal TRAb levels. Serum T3, FT4, TSH, TRAb levels were 
      measured using electrochemiluminescence immunoassay. RESULTS: 51 pregnant women 
      were included. Five women had adverse pregnancy outcomes, TRAb levels of 
      > 19.06 IU/L (10.9 times the upper limit of normal (ULN)) predicted adverse 
      pregnancy outcomes with 100% sensitivity and 93.5% specificity. Among the 46 
      successful live births, 13 (28.3%) had neonatal thyroid dysfunction. Out of 13 
      neonates, 7 (32%) had neonatal thyrotoxicosis, 4 (18%) had primary 
      hypothyroidism, and 2 (9%) had central hypothyroidism. Third trimester maternal 
      TRAb levels of > 7.99 IU/L (4.6 times the ULN)and day three neonatal TRAb levels 
      of > 5.03 IU/L (2.9 times the ULN), predicted the neonatal thyrotoxicosis with 
      100% sensitivity and 97.4% specificity. CONCLUSION: Very high maternal third 
      generation TRAb levels strongly predicted the adverse pregnancy outcomes and 
      neonatal thyroid dysfunction in pregnant women with Graves' disease. Neonatal 
      thyroid function test along with the TRAb levels strongly correlated with 
      different forms of neonatal thyroid dysfunction and is very useful in avoiding 
      inadvertent treatment to neonates.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Priyanka, Raghavendran
AU  - Priyanka R
AD  - Department of Endocrinology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India.
FAU - Sridhar, Subbiah
AU  - Sridhar S
AUID- ORCID: 0000-0001-5451-0848
AD  - Department of Endocrinology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India. drsridharjipmer@gmail.com.
FAU - Sumathi, Baskaran
AU  - Sumathi B
AD  - Department of Obstetrics and Gynecology, Madurai Medical College & Govt. Rajaji 
      Hospital, Madurai, 625 020, Tamil Nadu, India.
FAU - Jeyaraj, Ashok Raja
AU  - Jeyaraj AR
AD  - Department of Endocrinology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India.
AD  - Department of Neonatology, Madurai Medical College & Govt Rajaji Hospital, 
      Madurai, India.
FAU - Natarajan, Vasanthiy
AU  - Natarajan V
AD  - Department of Endocrinology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India.
FAU - Subbiah, Eagappan
AU  - Subbiah E
AD  - Department of Diabetology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India.
FAU - Raghavan, Kasthuri Santharam
AU  - Raghavan KS
AD  - Department of Diabetology, Madurai Medical College & Govt. Rajaji Hospital, 
      Madurai, 625 020, Tamil Nadu, India.
FAU - Sangumani, Jayaraman
AU  - Sangumani J
AD  - Dean, Government Medical College, Virudhunagar, Virudhunagar, 626001, Tamil Nadu, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20231020
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
SB  - IM
OTO - NOTNLM
OT  - Graves' disease
OT  - Hyperthyroidism
OT  - Thyroid storm
OT  - Thyrotoxicosis
OT  - Thyrotropin Receptor Antibody (TRAb)
EDAT- 2023/10/20 12:44
MHDA- 2023/10/20 12:44
CRDT- 2023/10/20 11:13
PHST- 2023/07/10 00:00 [received]
PHST- 2023/10/09 00:00 [accepted]
PHST- 2023/10/20 12:44 [medline]
PHST- 2023/10/20 12:44 [pubmed]
PHST- 2023/10/20 11:13 [entrez]
AID - 10.1007/s12020-023-03569-3 [pii]
AID - 10.1007/s12020-023-03569-3 [doi]
PST - aheadofprint
SO  - Endocrine. 2023 Oct 20. doi: 10.1007/s12020-023-03569-3.